Clinical trial
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
NCT00486278 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00486278 |
|---|---|
| Title | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds |
| Official title | A Multi-centre, Randomised, Double-blinded, Controlled, Dose-escalation Trial on Safety and Efficacy of Activated Recombinant FVII Analogue (NN1731) in the Treatment of Joint Bleeds in Congenital Haemophilia Patients With Inhibitors |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Haemophilia A, Haemophilia B |
| Intervention type | Drug |
| Interventions | eptacog alfa (activated), vatreptacog alfa (activated) |
| Enrollment | 51 |
| Start date | Jun 1, 2007 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Jun 14, 2007 |
| Last update posted | Mar 7, 2017 |
| Countries | Argentina, Brazil, Canada, Croatia, France, Hungary, Israel, Italy, Japan, Malaysia, Poland, South Africa and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: